



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Vemurafenib](#) > [Printer-friendly PDF](#)

---

# Vemurafenib

**Trade Name:**

Zelboraf

**Manufacturer/Distributor:**

Hoffman-La Roche Ltd.

[www.rochecanada.com](http://www.rochecanada.com) 1-888-762-4388

**Classification:**

Protein kinase inhibitor

**ATC Class:**

L01XE15 - Vemurafenib

**Status:**

active

**Notice of Compliance (yyyy/mm/dd):**

2012/02/15

**Date Marketed in Canada (yyyy/mm/dd):**

2012/03/06

**Presentation:**

Tablet: 240 mg. DIN: 02380242

**Comments:**

Indicated as monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. Should only be prescribed and supervised by a qualified physician experienced in the use of anti-cancer agents.

**Keywords:** vemurafenib  
melanoma

**Access:**

public

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?l?ilw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call

your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

#### **Terms and Conditions**

---

**Source URL (retrieved on 2025-04-18 20:15):** <http://www.dpic.org/druglisting/vemurafenib>